Chauhan, Jitesh
Grandits, Melanie
Palhares, Lais C. G. F.
Mele, Silvia
Nakamura, Mano
López-Abente, Jacobo
Crescioli, Silvia
Laddach, Roman
Romero-Clavijo, Pablo http://orcid.org/0000-0003-4380-3308
Cheung, Anthony http://orcid.org/0000-0002-2988-2786
Stavraka, Chara http://orcid.org/0000-0001-7623-299X
Chenoweth, Alicia M.
Sow, Heng Sheng
Chiaruttini, Giulia
Gilbert, Amy E.
Dodev, Tihomir
Koers, Alexander
Pellizzari, Giulia http://orcid.org/0000-0003-0387-1912
Ilieva, Kristina M.
Man, Francis http://orcid.org/0000-0002-5076-2180
Ali, Niwa
Hobbs, Carl
Lombardi, Sara
Lionarons, Daniël A.
Gould, Hannah J. http://orcid.org/0000-0003-0411-688X
Beavil, Andrew J. http://orcid.org/0000-0002-0768-122X
Geh, Jenny L. C. http://orcid.org/0000-0001-7031-3844
MacKenzie Ross, Alastair D. http://orcid.org/0000-0001-7299-8656
Healy, Ciaran
Calonje, Eduardo
Downward, Julian http://orcid.org/0000-0002-2331-4729
Nestle, Frank O.
Tsoka, Sophia
Josephs, Debra H.
Blower, Philip J.
Karagiannis, Panagiotis
Lacy, Katie E.
Spicer, James http://orcid.org/0000-0003-3732-8491
Karagiannis, Sophia N. http://orcid.org/0000-0002-4100-7810
Bax, Heather J. http://orcid.org/0000-0003-0432-4160
Funding for this research was provided by:
DH | National Institute for Health Research (IS-BRC-1215-20006)
Cancer Research UK (C30122/A11527; C30122/A15774)
Department of Health | National Health and Medical Research Council (MR/L023091/1)
Guy's and St Thomas' Charity (Melanoma special fund - 573)
Breast Cancer Now (147; KCL-BCN-Q3)
Innovate UK (51746)
Rotary Foundation
Article History
Received: 3 February 2022
Accepted: 31 March 2023
First Online: 25 April 2023
Competing interests
: J.S. and S.N.K. are founders and shareholders of Epsilogen Ltd. S.N.K., J.S., D.H.J., G.P., and H.J.B. declare patents on antibodies for cancer. J.C., M.G., J.L-A, H.S.S, and H.J.B have been employed through a fund provided by Epsilogen Ltd. P.K. has conducted advisory work for Janssen and is stockholder in Abbvie. J.D. has acted as a consultant for AstraZeneca, Jubilant, Theras, BridgeBio and Vividion, and has funded research agreements with BMS and Revolution Medicines. All other authors declare no competing interests.